Alimera Sciences, which is developing an injectable implant to treat eye diseases, will see its quiet period end on Monday, May 31st. On April 21st, the company raised $72.1 million by offering 6.6 million shares at $11, below the range of $15-$17. Credit Suisse and Citi acted as lead managers on the deal.
